Pyrrolopyrimidine compounds as cdk inhibitors

The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need...

Full description

Saved in:
Bibliographic Details
Main Authors LI YUE, SUNG MOO, DAGOSTIN CLAUDIO, BROOKS CLINTON A, MORTENSON PAUL, SMITH TROY, BESONG GILBERT, HE GUO, HOWARD STEVEN, WRONA WOJCIECH, BRAIN CHRISTOPHER THOMAS, CONGREVE MILES STUART, HOU YING, LU YIPIN, WOODHEAD STEVEN
Format Patent
LanguageChinese
English
Published 24.09.2014
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
Bibliography:Application Number: CN200980141314